These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 20546528

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease.
    Lee KY, Lee HS, Hong JH, Han JW, Lee JS, Whang KT.
    J Trop Pediatr; 2005 Apr; 51(2):98-101. PubMed ID: 15677370
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease.
    Wang CL, Wu YT, Lee CJ, Liu HC, Huang LT, Yang KD.
    J Pediatr; 2002 Oct; 141(4):560-5. PubMed ID: 12378198
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
    Friedman KG, Gauvreau K, Hamaoka-Okamoto A, Tang A, Berry E, Tremoulet AH, Mahavadi VS, Baker A, deFerranti SD, Fulton DR, Burns JC, Newburger JW.
    J Am Heart Assoc; 2016 Sep 15; 5(9):. PubMed ID: 27633390
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
    Yoshimura K, Kimata T, Mine K, Uchiyama T, Tsuji S, Kaneko K.
    J Pediatr; 2013 Jun 15; 162(6):1205-9. PubMed ID: 23290510
    [Abstract] [Full Text] [Related]

  • 56. Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression.
    Millar K, Manlhiot C, Yeung RS, Somji Z, McCrindle BW.
    Int J Cardiol; 2012 Jan 12; 154(1):9-13. PubMed ID: 20851480
    [Abstract] [Full Text] [Related]

  • 57. Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment.
    Downie ML, Manlhiot C, Collins TH, Chahal N, Yeung RSM, McCrindle BW.
    Int J Cardiol; 2017 Jun 01; 236():157-161. PubMed ID: 28089146
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome.
    Morici MV, Galen WK, Shetty AK, Lebouef RP, Gouri TP, Cowan GS, Gedalia A.
    J Rheumatol; 2000 Oct 01; 27(10):2494-7. PubMed ID: 11036849
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.